Dyne Therapeutics
Waltham, Massachusetts, United States · Biotechnology, Health Care, Therapeutics · 187 employees
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs
Funding history
- Funding Round — $328.6M — Dec 2025
- Funding Round — $115.7M — Aug 2020
Recent signals
- Dec 10, 2025: Raised $328.6M
- Dec 09, 2025: SEC 8-K (1.01): On December 9, 2025, Dyne Therapeutics, Inc. entered into an Underwriting Agreement with Morgan Stanley & Co. LLC, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated, and Guggenheim Securities, LLC for an underwritten public offering of 18,980,478 shares of its common stock at a public offering price of $18.44 per share. The Underwriters will purchase these shares from the Company at a price of $17.3336 per share. This offering is significant as it may help Dyne Therapeutics raise substantial capital, potentially impacting its business operations and strategic initiatives moving forward.
- Mar 20, 2025: Dyne Therapeutics Appoints Erick J. Lucera as Chief Financial Officer
- Sep 03, 2024: Dyne Therapeutics Appoints Doug Kerr as Chief Medical Officer and Johanna Friedl-Naderer as Chief Commercial Officer
- Mar 25, 2024: John Cox Named President and CEO of Dyne Therapeutics
- Aug 14, 2020: Raised $115.7M
See plans & pricing → Track Dyne Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.